Association of Hyperlipidaemia with 5-year Survival After Hospitalization for Acute Myocardial Infarction: A Propensity Score Matched Analysis -…

OBJECTIVES:

The primary objective was to examine the association between hyperlipidaemia (HLP) and 5-year survival after incident acutemyocardial infarction(AMI). The secondary objectives were to assess the effect of HLP on survival to discharge across patient subgroups, and the impact of statin prescription, intensity and long-term statin adherence on 5-year survival.

Retrospective cohort study of 7071 patients hospitalised for AMI at Mayo Clinic from 2001 through 2011. Of these, 2091 patients with HLP (age (meanSD) 69.713.5) were propensity score matched to 2091 patients without HLP (age 70.614.2).

In matched patients, HLP was associated with higher rate of survival to discharge than no HLP (95% vs 91%; log-rank <0.0001). At year 5, the adjusted HR for all-cause mortality in patients with HLP versus no HLP was 0.66 (95% CI 0.58-0.74), and patients with prescription statin versus no statin was 0.24 (95% CI 0.21 to 0.28). The mean survival was 0.35year greater in patients with HLP than in those with no HLP (95%CI 0.25 to 0.46). Patients with HLP gained on an average 0.17 life year and those treated with statin 0.67 life year at 5 years after AMI. The benefit of concurrent HLP was consistent across study subgroups.

In patients with AMI, concomitant HLP was associated with increased survival and a net gain in life years, independent of survival benefit from statin therapy. The results also reaffirm the role of statin prescription, intensity and adherence in reducing the mortality after incident AMI.

See the original post here:
Association of Hyperlipidaemia with 5-year Survival After Hospitalization for Acute Myocardial Infarction: A Propensity Score Matched Analysis -...